Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Partners with ImmVirX to Launch Clinical Study Combining Tyvyt and IVX037

Fineline Cube Feb 21, 2024

Innovent Biologics Inc. (HKG: 1801), based in China, has announced the signing of a clinical...

Company

Biogen Appoints Ding Weibo as Head of Asia-Pacific Region, Succeeding Francis Wan

Fineline Cube Feb 21, 2024

Biogen (NASDAQ: BIIB) has announced the appointment of Ding Weibo as the new head of...

Company Deals

Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion

Fineline Cube Feb 21, 2024

Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in...

Company Drug

Mabwell Bioscience Receives FDA Green Light for B7-H3 Targeting ADC 7MW3711

Fineline Cube Feb 20, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

BMS and Sichuan Biokin Commence Joint Development of EGFR/HER3-Targeted ADC

Fineline Cube Feb 20, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced that a...

Company Deals

Everest Medicines Terminates Agreement with Providence Therapeutics, Retains mRNA Rights

Fineline Cube Feb 20, 2024

Everest Medicines (HKG: 1952), a biopharmaceutical company based in China, has announced the termination of...

Company Drug

Jacobio Pharma Gets CDE Green Light for Phase III Study Combining Gleevec Inhibitors in NSCLC

Fineline Cube Feb 20, 2024

Jacobio Pharma (HKG: 1167), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

Neurophth Biotechnology Completes Enrollment and Dosing in US Clinical Study for ND4-LHON Gene Therapy

Fineline Cube Feb 20, 2024

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced the completion...

Company Deals

Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences

Fineline Cube Feb 20, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody...

Company Deals

Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization

Fineline Cube Feb 20, 2024

Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a...

Company Drug

Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Feb 20, 2024

Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...

Company Drug

ImmunoTech Biopharm Gets NMPA Green Light for Clinical Study of aT19 Injection for B-ALL

Fineline Cube Feb 20, 2024

ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based...

Policy / Regulatory

Beijing, Tianjin, and Hebei Release Draft Proposal for Updated Drug Clinical Trial Inspection Standards

Fineline Cube Feb 20, 2024

The medical products administration bureaus of Beijing, Tianjin, and Hebei province have released a draft...

Company Drug

AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC

Fineline Cube Feb 20, 2024

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...

Company Drug

Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease

Fineline Cube Feb 20, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...

Policy / Regulatory

China’s CDE Issues Guiding Principles for ADC Research and Evaluation

Fineline Cube Feb 20, 2024

China’s Center for Drug Evaluation (CDE) has issued a notification outlining the “Guiding Principles for...

Company Legal / IP Policy / Regulatory

GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book

Fineline Cube Feb 20, 2024

Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade...

Company Deals

Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies

Fineline Cube Feb 19, 2024

Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...

Company Drug

Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint

Fineline Cube Feb 19, 2024

Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...

Policy / Regulatory

China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...

Posts pagination

1 … 430 431 432 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.